Karuna Therapeutics, Inc.
KRTX
|
$329.83
0.0%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (67.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (672.96% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 12,599,265,884
http://www.karunatx.com
Sec Filling | Patents | 19 employees
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders.The company was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.
nervous system msa schizophrenia
add to watch list Paper trade email alert is off
Press-releases
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Published: 2024-03-18 (Crawled : 15:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
acquisition therapeutics
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
acquisition
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
Published: 2024-02-15 (Crawled : 09:00) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.01%
H: 0.03%
C: -0.02%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.25%
H: 2.59%
C: 0.88%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.75%
H: 0.19%
C: -0.46%
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02 (Crawled : 14:30) - biospace.com/
RYZB | $62.49 0.03% 280K
|
|
| O: 0.03%
H: 0.11%
C: 0.0%
XYF | News | $3.815 -1.74% 0.39% 5.4K
|
Finance
|
| O: 1.04%
H: 1.79%
C: -1.23%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
financial results
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
Published: 2024-01-08 (Crawled : 22:00) - prnewswire.com
BSX | $72.91 5.68% -0.03% 15M
|
Health Technology
|
| O: -0.38%
H: 2.06%
C: 1.77%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 0.03%
H: 0.21%
C: 0.1%
AXNX | $66.67 0.3% 0.3% 400K
|
Health Technology
|
| O: -0.63%
H: 0.23%
C: 0.19%
acquisition
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Callon Petroleum Company
Published: 2024-01-04 (Crawled : 22:00) - prnewswire.com
APA | $32.06 0.0% 4.5M
|
Energy Minerals
|
| O: 0.76%
H: 0.5%
C: 0.09%
company acquisition
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.
Published: 2023-12-22 (Crawled : 21:00) - prnewswire.com
KRTX | $329.83 0.0% 1.9M
|
Health Technology
| Email alert
Add to watchlist
PGTI | $41.99 -0.0% 2.2M
|
Producer Manufacturing
| Email alert
Add to watchlist
AYX | $48.26 0.0% 6.8M
|
Technology Services
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
PGTI | $41.99 -0.0% 2.2M
|
Producer Manufacturing
| Email alert
Add to watchlist
acquisition
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Published: 2023-12-22 (Crawled : 20:00) - biospace.com/
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: 29.67%
H: 0.0%
C: -5.76%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.78%
H: 5.15%
C: 2.81%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 47.74%
H: 0.0%
C: 0.0%
therapeutics acquired
PureTech Year End Update and Outlook for 2024
Published: 2023-12-20 (Crawled : 09:00) - biospace.com/
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: 0.0%
H: 0.0%
C: 0.0%
AKLI | $0.249 4.18% 4.02% 150K
|
|
| O: -5.18%
H: 25.58%
C: 14.44%
VOR | $1.745 -7.18% -7.74% 290K
|
|
| O: 2.11%
H: 2.48%
C: -5.37%
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -0.3%
H: 0.97%
C: -2.76%
year update
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
Published: 2023-12-14 (Crawled : 00:00) - biospace.com/
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
lancet publication schizophrenia trial therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10